Table 2. Association of CRP and SCC-Ag levels at the time of recurrence (N = 100).
| CRP (−), SCC-Ag (−) | CRP (−), SCC-Ag (+) | CRP (+), SCC-Ag (−) | CRP (+), SCC-Ag (+) | ||
| [n (%)] | [n (%)] | [n (%)] | [n (%)] | P value | |
| Recurrent tumor stage | |||||
| I (n = 11) | 9 (81.8) | 1 (9.1) | 1 (9.1) | 0 (0.0) | <0.001 |
| II (n = 11) | 7 (63.6) | 0 (0.0) | 4 (36.4) | 0 (0.0) | |
| III (n = 7) | 6 (85.7) | 0 (0.0) | 1 (14.3) | 0 (0.0) | |
| IVa (n = 39) | 15 (38.5) | 3 (7.7) | 14 (35.9) | 7 (17.9) | |
| IVb (n = 4) | 2 (50.0) | 1 (25.0) | 1 (25.0) | 0 (0.0) | |
| IVc(n = 28) | 3 (10.7) | 3 (10.7) | 7 (25.0) | 15 (53.6) | |
| Recurrent primary tumor status | |||||
| T0 (n = 38) | 11 (28.9) | 2 (5.3) | 9 (23.7) | 16 (42.1) | 0.064 |
| T1 (n = 11) | 9 (81.8) | 1 (9.1) | 1 (9.1) | 0 (0.0) | |
| T2 (n = 14) | 8 (57.1) | 1 (7.1) | 4 (28.6) | 1 (7.1) | |
| T3 (n = 3) | 2 (66.7) | 0 (0.0) | 1 (33.3) | 0 (0.0) | |
| T4a (n = 28) | 10 (35.7) | 3 (10.7) | 11 (39.3) | 4 (14.3) | |
| T4b (n = 6) | 2 (33.3) | 1 (16.7) | 2 (33.3) | 1 (16.7) | |
| Recurrent nodal status | |||||
| N0 (n = 63) | 29 (46.0) | 5 (7.9) | 20 (31.7) | 9 (14.3) | 0.011 |
| N1 (n = 5) | 5 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| N2 (n = 32) | 8 (25.0) | 3 (9.4) | 8 (25.0) | 13 (40.6) | |
| Distant metastasis | |||||
| No (n = 72) | 39 (54.2) | 5 (6.9) | 21 (29.2) | 7 (9.7) | <0.001 |
| Yes (n = 28) | 3 (10.7) | 3 (10.7) | 7 (25.0) | 15 (53.6) |
CRP (−), CRP level <5.0 mg/L; CRP (+), CRP level ≥5.0 mg/L; SCC-Ag (−), SCC-Ag <2.0 ng/ml; SCC-Ag (+), SCC-Ag ≥2.0 ng/ml.